Skip to content
All Podcasts – Lifestyle
Author:
ABLi Therapeutics
ABLi Therapeutics Announces Outcomes from its Parkinson’s-related Biomarker Study Demonstrating Modification of Human Disease with Risvodetinib
August 4, 2026
ABLi Therapeutics Appoints Industry Veteran Dr. Rachelle S. Doody to its Board of Directors
May 6, 2026
ABLi Therapeutics to Present at the Citizens Life Sciences Conference
March 6, 2026